Immune cells and chemotherapy response in young triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how certain immune cells (senescent T cells) in young women with triple-negative breast cancer affect how well chemotherapy works. If you join, researchers will study your blood and tumor samples to see if these cells can predict treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 40 or younger.
- You have been diagnosed with triple-negative breast cancer (ER-, PR-, HER2-).
- Your doctor plans to give chemotherapy before surgery because your tumor is larger than 2 cm, or has spread to lymph nodes, or you want breast-conserving surgery but need chemo first.
- Your cancer has not spread to distant organs (not stage IV) and you have not had another cancer.
- You do not have an active infection, autoimmune disease, HBV, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This trial studies a simple blood test that may predict how well your body responds to chemotherapy plus immunotherapy before surgery for triple-negative breast cancer. The goal is to use these clues to personalize your treatment in the future.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
Hear when a new Chemotherapy Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.